-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Genmab, Lowers Price Target to $39

Benzinga·01/20/2026 11:42:08
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Genmab (NASDAQ:GMAB) with a Buy and lowers the price target from $41 to $39.